;
Skip to main content
Home > Week in Review > Other News

Chronological Index of : Other News

 Current Issue
  • Alnylam infectious news

    Alnylam Pharmaceuticals Inc. (NASDAQ:ALNY), Cambridge, Mass. Business: Infectious Alnylam unveiled two new RNAi therapeutic candidates in its hepatic infectious diseases portfolio at the American Association for the …

    Published on 11/17/2014
  • Dendreon cancer news

    Dendreon Corp. (NASDAQ:DNDN), Seattle, Wash. Business: Cancer Dendreon filed Chapter 11 bankruptcy in the U.S. Bankruptcy Court for the District of Delaware and said it will begin taking bids for its assets. The company…

    Published on 11/17/2014
  • Takeda cardiovascular news

    Takeda Pharmaceutical Co. Ltd. (Tokyo:4502), Osaka, Japan Business: Cardiovascular Takeda announced new measures and disciplinary action as a result of inappropriate promotional activities utilizing results of the …

    Published on 11/17/2014
  • Amgen, Novartis biosimilars news

    Amgen Inc. (NASDAQ:AMGN), Thousand Oaks, Calif. Novartis AG (NYSE:NVS; SIX:NOVN), Basel, Switzerland Business: Biosimilars Amgen submitted a Citizen's Petition to FDA asking the agency to require that biosimilar …

    Published on 11/10/2014
  • AMAG Pharmaceuticals, Silverstrand Investments hematology news

    AMAG Pharmaceuticals Inc. (NASDAQ:AMAG), Lexington, Mass. Silverstrand Investments, location undisclosed Business: Hematology AMAG will pay $3.8 million to settle a class action lawsuit -- Silverstrand Investments, et …

    Published on 11/3/2014
  • Amgen, Novartis biosimilars news

    Amgen Inc. (NASDAQ:AMGN), Thousand Oaks, Calif. Novartis AG (NYSE:NVS; SIX:NOVN), Basel, Switzerland Business: Biosimilars Amgen filed a lawsuit in the U.S. District Court for the Northern District of California …

    Published on 11/3/2014
  • Eli Lilly, Takeda endocrine/metabolic news

    Eli Lilly and Co. (NYSE:LLY), Indianapolis, Ind. Takeda Pharmaceutical Co. Ltd. (Tokyo:4502), Osaka, Japan Business: Endocrine/Metabolic A judge in the U.S. District Court for the Western District of Louisiana issued an…

    Published on 11/3/2014
  • Fujifilm, MediVector infectious news

    Fujifilm Holdings Corp. (Tokyo:4901), Tokyo, Japan MediVector Inc., Boston, Mass. Business: Infectious Fujifilm's Toyama Chemical Co. Ltd. unit began producing 200 mg Avigan favipiravir in preparation for clinical …

    Published on 11/3/2014
  • greenovation endocrine/metabolic news

    greenovation Biotech GmbH, Heilbronn, Germany Business: Endocrine/Metabolic greenovation said it produced the world's first GMP-compliant batch of drug substance manufactured in moss for clinical use. The substance, …

    Published on 11/3/2014
  • J&J pharmaceuticals news

    Johnson & Johnson (NYSE:JNJ), New Brunswick, N.J. Business: Pharmaceuticals Johnson & Johnson launched its Asia-Pacific Innovation Center, the fourth of J&J's centers. Located in Shanghai with satellite offices in …

    Published on 11/3/2014
  • Medicines Co., Mylan cardiovascular news

    The Medicines Co. (NASDAQ:MDCO), Cambridge, Mass. Mylan Inc. (NASDAQ:MYL), Canonsburg, Pa. Business: Cardiovascular The U.S. District Court for the Northern District of Illinois ruled that Mylan's ANDA submission to FDA…

    Published on 11/3/2014
  • Myriad Genetics pharmacogenetics news

    Myriad Genetics Inc. (NASDAQ:MYGN), Salt Lake City, Utah Business: Pharmacogenetics Myriad established a European lab for its companion diagnostic Tumor BRACAnalysis CDx. The test identifies patients with breast cancer …

    Published on 11/3/2014
  • Actavis, Purdue Pharma neurology news

    Actavis plc (NYSE:ACT), Dublin, Ireland Purdue Pharma L.P., Stamford, Conn. Business: Neurology Purdue Pharma filed suit in the U.S. District Court for the District of Delaware alleging that an ANDA submitted by Actavis…

    Published on 10/27/2014
  • Ambry Genetics, Dana-Farber Cancer Institute, Mayo Clinic, Memorial Sloan Kettering, University of Pennsylvania cancer news

    Ambry Genetics Corp., Alliso Viejo, Calif. Dana-Farber Cancer Institute, Boston, Mass. Mayo Clinic, Rochester, Minn. Memorial Sloan Kettering Cancer Center, New York, N.Y. University of Pennsylvania, Philadelphia, Pa. …

    Published on 10/27/2014
  • Amgen, Third Point LLC biopharmaceuticals news

    Amgen Inc. (NASDAQ:AMGN), Thousand Oaks, Calif. Third Point LLC, New York, N.Y. Business: Biopharmaceuticals Activist investor Third Point outlined a plan for increasing Amgen's valuation by more than 80% in the next …

    Published on 10/27/2014
  • Baxter pharmaceuticals, biosimilars, cancer news

    Baxter International Inc. (NYSE:BAX), Deerfield, Ill. Business: Pharmaceuticals, Biosimilars, Cancer This year, Baxter plans to begin work on a new global innovation and R&D center in Cambridge, Massachusetts, for the …

    Published on 10/27/2014
  • GlaxoSmithKline, Novartis pharmaceuticals news

    GlaxoSmithKline plc (LSE:GSK; NYSE:GSK), London, U.K. Novartis AG (NYSE:NVS; SIX:NOVN), Basel, Switzerland Business: Pharmaceuticals GlaxoSmithKline disclosed in its 3Q14 earnings call that it reshuffled its executive …

    Published on 10/27/2014
  • J&J, Texas Medical Center, Yale School of Medicine pharmaceuticals, other news

    Johnson & Johnson (NYSE:JNJ), New Brunswick, N.J. Texas Medical Center, Houston, Texas Yale School of Medicine, New Haven, Conn. Business: Pharmaceuticals, Other Johnson & Johnson plans to open the fourth incubator in …

    Published on 10/27/2014
  • ViaCtye Inc., California Institute for Regenerative Medicine endocrine/metabolic news

    ViaCtye Inc., San Diego, Calif. California Institute for Regenerative Medicine (CIRM), San Francisco, Calif. Business: Endocrine/Metabolic CIRM awarded ViaCyte an additional $16.6 million to support clinical testing of …

    Published on 10/27/2014
  • Viamet cancer, infectious news

    Viamet Pharmaceuticals Inc., Durham, N.C. Business: Cancer, Infectious Viamet said it will spin out its prostate cancer program to existing investors in a newco called Innocrin Pharmaceuticals, led by former Viamet CSO …

    Published on 10/27/2014
  • Amgen, Regeneron, Sanofi endocrine/metabolic news

    Amgen Inc. (NASDAQ:AMGN), Thousand Oaks, Calif. Regeneron Pharmaceuticals Inc. (NASDAQ:REGN), Tarrytown, N.Y. Sanofi (Euronext:SAN; NYSE:SNY), Paris, France Business: Endocrine/Metabolic Amgen filed a suit in the U.S.…

    Published on 10/20/2014
  • Aptose Biosciences, Oregon Health & Science University, LLS cancer news

    Aptose Biosciences Inc. (TSX:APS; Pink:APSCF), Toronto, Ontario Oregon Health & Science University, Portland, Ore. The Leukemia & Lymphoma Society, White Plains, N.Y. Business: Cancer Aptose (formerly Lorus Therapeutics…

    Published on 10/20/2014
  • Coronado Biosciences dermatology news

    Coronado Biosciences Inc. (NASDAQ:CNDO), Burlington, Mass. Business: Dermatology Coronado formed Journey Medical Corp., a wholly owned subsidiary to acquire and license dermatology products for commercialization. The …

    Published on 10/20/2014
  • DecImmune Therapeutics, NIH cardiovascular news

    DecImmune Therapeutics Inc., Boston, Mass. National Institutes of Health, Bethesda, Md. Business: Cardiovascular DecImmune said NIH awarded the biotech a Phase IIB Small Business Innovation Research (SBIR) contract for…

    Published on 10/20/2014
  • Emergent BioSolutions, U.S. Department of Health and Human Services, NIH infectious news

    Emergent BioSolutions Inc. (NYSE:EBS), Rockville, Md. U.S. Department of Health and Human Services, Washington, D.C. National Institutes of Health, Bethesda, Md. Business: Infectious NIH's National Institute of Allergy…

    Published on 10/20/2014

< Previous   1  2  3  4  5  Next >
Subscribe Now
Free Trial

About BioCentury

Decision-shaping business intelligence for the global biotech and pharma industry since 1993